Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics (NASDAQ:TENX) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Tenax Therapeutics and Gyre Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1	0	3	0	2.50
Gyre Therapeutics	1	1	3	0	2.40

Tenax Therapeutics currently has a consensus price target of $21.67, indicating a potential upside of 102.68%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 120.49%. Given Gyre Therapeutics’ higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Tenax Therapeutics.

Insider & Institutional Ownership

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by company insiders. Comparatively, 10.0% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Tenax Therapeutics has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.

Earnings & Valuation

This table compares Tenax Therapeutics and Gyre Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$17.60 million	($1.13)	-9.46
Gyre Therapeutics	$105.76 million	7.02	$12.09 million	$0.03	257.00

Gyre Therapeutics has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tenax Therapeutics and Gyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-43.24%	-41.52%
Gyre Therapeutics	6.20%	9.50%	7.87%

Summary

Gyre Therapeutics beats Tenax Therapeutics on 11 of the 12 factors compared between the two stocks.

About Tenax Therapeutics

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.